Mr. Markus Meile reports

PROGRESS UPDATE ON SECURITIES

Medmira Inc. has completed, with its transfer agent, its process and has received confirmation by the TSX Venture Exchange.

"Further to the resumption of trading of the shares of Medmira Inc., the exchange advises that effective at the opening, Friday, Sept. 1, 2023, the shares of the company will resume trading. The exchange bulletin will be dated Aug. 30, 2022, and will be available on our website tomorrow at 1 p.m. PST."

While the processing time was longer than anticipated, the company is pleased with the conclusion of this.

The company will provide a press release with regard to its current Health Canada submission and continuing clinical trials prior to Sept. 14, 2023.

About Medmira Inc.

Medmira is a leading developer and manufacturer of rapid vertical flow technology diagnostics. The company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2, in just three easy steps. The company's tests are sold globally under the Reveal, RevealCOVID-19, Multiplo and Miriad brands. Based on its patented rapid vertical flow technology, Medmira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. Medmira's corporate offices and manufacturing facilities are located in Halifax, N.S., Canada.

We seek Safe Harbor.